Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc.…
Over 250 million people worldwide unaware they have diabetes, according to new research from the International Diabetes Federation (IDF)
New estimates from the IDF Diabetes Atlas highlight the growing diabetes threat,…
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
Cycling Through Life with MS: Paul James Journey with Bike the UK for MS
Tuesday 4 March, 2025 From the RAF to the Road: Meet Paul…
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Based on more than six months of additional monitoring, data show continued…